Долак (Ketorolac) is commonly used to help with the short-term management of pain that creates noticeable physiological strain.

What Долак Treats: Main Uses and Benefits

Долак is primarily applied across domains where symptomatic discomfort is high, addressing symptoms related to physical discomfort that appear suddenly. It is generally used in conditions presenting with acute episodes, such as pain following major physical stressors like surgical interventions or trauma, and musculoskeletal pain that creates noticeable physiological strain. It also is relevant in contexts requiring targeted support for specialized symptoms, including the spasmodic pain linked to organ-specific functional stress, such as renal colic, and localized discomfort after eye surgery. The medication contributes to improved comfort during challenging acute phases.

Quick Fact: Support for Acute Symptoms

The medication is relevant for easing discomfort that significantly interferes with daily functioning.

In clinical settings that involve acute or unstable symptom patterns, this short-term symptomatic assistance may assist with maintaining functional stability during symptomatic periods. By helping to moderate symptoms that create noticeable physiological strain, it provides support that helps ease the overall symptom burden.

Regulatory References

1. NIH MedlinePlus overview

Who can and cannot use Долак (Colchicine) — Official Regulatory Information

The use of Долак (colchicine) is generally allowed for adults without specific underlying health conditions or drug interactions that pose a risk of serious toxicity. However, the medicine has a narrow therapeutic index, meaning there is a small difference between a therapeutic dose and a toxic dose, which leads to strict eligibility requirements based on organ function and concomitant medications.

Populations for whom use is Contraindicated

Official labeling strictly prohibits the use of colchicine in the following groups due to the high risk of severe or fatal toxicity:

• Patients with severe renal impairment or renal failure (creatinine clearance less than 15 mL/minute).
• Patients with severe hepatic impairment.
• Patients with pre-existing blood dyscrasias (e.g., myelosuppression, leukopenia, thrombocytopenia).
• Patients who are taking strong inhibitors of CYP3A4 or P-glycoprotein (P-gp), as these greatly increase colchicine concentration in the body.

Use with Caution and Restrictions

• Impaired Organ Function: Patients with mild to moderate renal or hepatic impairment should be closely monitored for adverse effects. Dose adjustments or alternative therapies may be necessary.
• Older Adults (Geriatric Use): Caution is advised due to the higher frequency of decreased renal and hepatic function in older patients, necessitating close monitoring.
• Pregnancy and Lactation: Use during pregnancy is generally considered only if the potential benefit justifies the risk. Caution is advised when administering the drug to a nursing woman, as it is excreted into breast milk.

This summary is for eligibility classification only and does not contain dosing, safety, or administration instructions.

Interactions with other medicines and products

The interaction profile for Долак (Ketorolac) establishes mandatory restrictions and cautions concerning co-administration with other medicinal products, primarily based on pharmacokinetic and pharmacodynamic effects documented in regulatory labeling.

Contraindicated Combinations

The following combinations are formally contraindicated due to the high risk of serious adverse outcomes:

• Other Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Co-administration is prohibited due to the risk of cumulative gastrointestinal (GI) toxicity and bleeding.
• Probenecid: Prohibited because it significantly increases the exposure of ketorolac by inhibiting its renal clearance.
• Pentoxifylline: Prohibited due to an officially documented increased risk of bleeding.

---

Pharmacodynamic and Clearance Interactions

Co-administration with several substance classes requires caution due to documented interaction outcomes:

• Bleeding Risk Reinforcement: Combining Долак with Anticoagulants (e.g., Warfarin), Antiplatelet Agents, SSRIs, or Corticosteroids increases the officially documented risk of serious bleeding events.
• Altered Exposure: Ketorolac may increase the plasma concentrations of Lithium and Digoxin by reducing their renal clearance. Co-administration with Methotrexate has the potential to reduce its clearance.
• Antihypertensive Agents: Ketorolac may officially reduce the antihypertensive effect of ACE Inhibitors or ARBs and the natriuretic effect of Diuretics.

---

Population-Specific Notes

The risk and severity of gastrointestinal and renal impairment interactions are officially noted as generally heightened in Elderly Patients.

Targeting the Cyclooxygenase ( COX) Enzymes

The action of Долак (Ketorolac tromethamine) is based on altering specific biological pathways to modulate the activity of prostaglandin synthesis, which is associated with nociceptive and inflammatory signaling. Its mechanistic activity is centered on enzyme inhibition within the Arachidonic Acid Cascade. Долак's primary mechanism is the non-selective competitive inhibition of the COX-1 and COX-2 enzymes. This action suppresses the initial molecular step for the synthesis of prostaglandins, which are regulatory mediators.

⬇️ Suppressing Prostaglandin-Mediated Signaling

By blocking COX activity, the drug limits the production of prostaglandins both at the site of tissue injury and within the central nervous system. This change results in the modulation of nociceptive signaling (pain transmission) and the chemical processes associated with local inflammatory responses.

Resulting Physiological Modulation

The systemic reduction in prostaglandin levels translates into the physiological consequence of reduced pain signal transmission through decreased pain receptor sensitization and modulation of inflammatory markers through the suppression of associated vascular changes. This core mechanistic action operates strictly within the pathways mediated by prostaglandins and does not interact with opioid or leukotriene pathways.

How Долак (Ketorolac) is Used

Долак is administered via specific, approved routes, and its use is strictly governed by time and dosage constraints outlined in official prescribing information. The medicine is available in several forms, including tablets (typically 10 mg), a solution for injection (for IM or IV use), a nasal spray, and an ophthalmic solution.

---

Administration and Dosage Principles

The total duration of systemic therapy, encompassing all forms such as the injection, nasal spray, and tablets, is officially limited and must not exceed 5 days. Oral administration is generally indicated only as continuation therapy following an initial period of intravenous (IV) or intramuscular (IM) dosing.

Usage Context	Standard Adult Dosing (≥ 50 kg)	Maximum Daily Dose	Frequency
IV/IM Injection	30 mg	120 mg	Every 6 hours
Oral Tablets	10 mg	40 mg	Every 4 to 6 hours
Older Adults/Impaired Patients	Reduced dose required	60 mg (IV/IM)	Adjusted

The IV injection must be administered as an undiluted bolus over no less than 15 seconds. Regulatory guidelines mandate using the lowest effective dosage for the shortest duration necessary, as increasing the dosage beyond the maximum labeled limits is not officially stated to improve efficacy.

---

Population and Procedural Constraints

Specific dosage reductions are required for certain populations to comply with official guidelines. For instance, the maximum total daily dose for the injectable solution must not exceed 60 mg for patients 65 years of age and older, those weighing less than 50 kg, or those with renal impairment. The safety and effectiveness of systemic use have not been established for children 17 years of age and younger.

Research Evidence / Overview of Studies for Долак (Ketorolac)

---

Evidence for Management of Acute Post-Surgical Pain

The foundation of research for injectable Долак was evaluated in the setting of acute pain following surgical procedures. This area was studied primarily through numerous short-term Randomized Controlled Trials (RCTs), where the medicine was evaluated alongside placebo or other analgesic agents in adult patients undergoing various major surgeries.

Studies monitored patterns where the administration of injectable Долак was observed in patients who experienced a change in measured pain intensity scores. Research also described patterns of opioid consumption, with studies reporting variations in the amount of supplementary opioid medication used during the immediate post-operative phase in the observed populations.

---

Evidence for Acute Pain in Emergency Care Settings

Долак was evaluated in research exploring short-term symptom changes for acute, severe pain conditions that frequently lead patients to emergency departments. This includes conditions associated with acute or disruptive episodes like renal colic and musculoskeletal trauma. The research mainly consisted of Randomized Controlled Trials that examined the injectable form, typically including adult patients.

The research examined outcomes related to physical discomfort, specifically tracking pain score reduction at very short, defined time intervals. Comparative studies reported that the level of symptom change measured was similar to the changes observed with certain opioid medications in these acute settings. Comparative evidence is lacking for the oral tablet form against other oral non-opioid pain relievers once patients have left the acute care environment.

---

Duration of Studies and Long-Term Outcomes

The vast majority of the research for systemic (whole-body) use of Долак is concentrated on short-term observation. The follow-up durations were limited, reflecting the medicine’s official designation for short-term management (typically le 5 days for the systemic forms).

This means that while the research contributes to understanding short-term changes, long-term outcomes are not well characterized. There is limited information for long-term outcomes regarding the durability of any observed response, and the research does not provide information for these extended periods.

Key Studies & References

1. Label: KETOROLAC TROMETHAMINE tablet - DailyMed - NIH (Regulatory/Systemic Dosage & Limitations)
2. KETOROLAC TROMETHAMINE TABLETS USP, 10 mg 0314 Rx only - DailyMed (Systemic Risks & Duration)

Common questions about Долак (FAQ)

---

Q: Is it safe to take Ketorolac if I'm on Lithium?

A: Official information indicates that taking Ketorolac along with Lithium may cause an increase in the concentration of Lithium in the bloodstream. This occurs because Ketorolac can reduce the body's clearance of Lithium. Due to the risk of serious toxicity from high Lithium levels, regulatory documents state that increased monitoring of a patient's Lithium levels may be required by a healthcare provider.

Q: What is the maximum oral dose of Долак for an adult per day?

A: According to the official prescribing information, the maximum total dose of the oral tablets per day is strictly limited for all adults. Official prescribing information states that the maximum total daily dose for the oral form should not be exceeded.

Q: What does Долак treat specifically (e.g., headache, tooth pain, post-op pain)?

A: Regulatory documents state that Ketorolac is indicated for the short-term management of moderately severe acute pain. This is typically pain that is severe enough to require an analgesic similar to an opioid in effect. Its use is generally intended for situations such as the immediate post-operative period following surgery.

Q: Can I drink alcohol while taking Ketorolac?

A: Official product information notes that using this medication with alcohol significantly increases the risk of serious gastrointestinal complications, such as internal bleeding and ulcers. Alcohol is explicitly cited as a factor that reinforces these documented risks.

Q: Is Долак a controlled substance?

A: Долак (Ketorolac) is classified as a potent Nonsteroidal Anti-inflammatory Drug (NSAID) and is a prescription-only medication. Official regulatory classification confirms that it is not scheduled or listed as a controlled substance under the U.S. Drug Enforcement Administration (DEA).

Q: How quickly does the injectable form of Долак start working?

A: Studies and official information indicate that the analgesic (pain-relieving) effect begins relatively quickly after receiving the injection. The onset of action for both intravenous and intramuscular forms is generally within approximately 30 minutes, with the maximum pain relief typically achieved within one to two hours.

Q: If I miss a dose of the Долак tablet, what should I do?

A: Regulatory documents state that if a dose is missed, the recommended procedure is to skip the missed dose and resume the normal dosing schedule. Patients are informed that they should not take a double dose to make up for the one that was missed.

How to Store and Dispose of Dolak (Ketorolac Tromethamine)

Dolak must be stored at controlled room temperature, maintaining a temperature range of 20 C to 25 C (68 F to 77 F). The original container must be used for storage to provide necessary protection from light and to maintain the integrity of the product.

Child Safety and Handling

It is officially required that this medicine be stored out of the sight and reach of children.

Disposal of Unused Medicine

Unused or expired Dolak should not be discarded into household waste or flushed down the toilet. Disposal must follow local environmental regulations for medicinal products, often requiring return to a pharmacy or an authorized pharmaceutical take-back scheme.